We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA AdCommittee Backs 6 Indications for Celltrion’s Biosimilar of Remicade
FDA AdCommittee Backs 6 Indications for Celltrion’s Biosimilar of Remicade
An FDA advisory committee gave Celltrion’s biosimilar candidate for Remicade a strong show of support Feb. 9, backing its approval for six different indications.